Φορτώνει......
Initial Testing (Stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program
BACKGROUND: Quisinostat (JNJ-26481585) is a second generation pyrimidyl-hydroxamic acid histone deacetylase (HDAC) inhibitor with high cellular potency towards class I and II HDACs. Quisinostat was selected for clinical development as it showed prolonged pharmacodynamic effects in vivo and demonstra...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Pediatr Blood Cancer |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2013
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4225045/ https://ncbi.nlm.nih.gov/pubmed/24038993 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24724 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|